Next Article in Journal
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
Next Article in Special Issue
Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy
Previous Article in Journal
Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic
Previous Article in Special Issue
PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis
Review

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials

Department of Lung Cancer and Chest Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(7), 2273; https://doi.org/10.3390/jcm9072273
Received: 22 May 2020 / Revised: 11 July 2020 / Accepted: 13 July 2020 / Published: 17 July 2020
Based on the results of the CheckMate 017 and CheckMate 057 studies, nivolumab therapy has become a new standard treatment for both squamous and non-squamous non-small-cell lung cancer (NSCLC). However, due to the specific inclusion criteria of these clinical trials, the efficacy and safety of nivolumab in real-world practice were not certain. In general, the real-world results of nivolumab treatment have been consistent with those obtained in clinical trials. Additional analyses of the real-world data have made the identification of prognostic factors possible. Good performance status is the most significant predictor of clinical benefit. Brain metastases, liver metastases, EGFR mutation, malignant pleural effusion, and a high number of metastatic sites were identified as negative prognostic factors. By contrast, a longer time to disease progression (>6 months) from the beginning of prior chemotherapy and an objective response to chemotherapy seem to have positive prognostic value in the case of nivolumab treatment. In terms of patient age, the data are inconclusive. Some blood biomarkers can also be considered significant prognostic factors. View Full-Text
Keywords: non-small-cell lung cancer; nivolumab; Expanded Access Program; real-world data; daily practice; prognostic factors non-small-cell lung cancer; nivolumab; Expanded Access Program; real-world data; daily practice; prognostic factors
MDPI and ACS Style

Knetki-Wróblewska, M.; Kowalski, D.M.; Krzakowski, M. Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials. J. Clin. Med. 2020, 9, 2273. https://doi.org/10.3390/jcm9072273

AMA Style

Knetki-Wróblewska M, Kowalski DM, Krzakowski M. Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials. Journal of Clinical Medicine. 2020; 9(7):2273. https://doi.org/10.3390/jcm9072273

Chicago/Turabian Style

Knetki-Wróblewska, Magdalena, Dariusz M. Kowalski, and Maciej Krzakowski. 2020. "Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials" Journal of Clinical Medicine 9, no. 7: 2273. https://doi.org/10.3390/jcm9072273

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop